Genzyme severs link with SYN-X on stroke technology
This article was originally published in Clinica
Executive Summary
Genzyme Diagnostics has modified its deal with SYN-X Pharma to commercialise a test for diagnosing, distinguishing and monitoring stroke. The two companies say that a new agreement supersedes their prior arrangements and "amicably resolves all prior disputes between them".